1. Home
  2. VRCA vs OTLK Comparison

VRCA vs OTLK Comparison

Compare VRCA & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VRCA
  • OTLK
  • Stock Information
  • Founded
  • VRCA 2013
  • OTLK 2010
  • Country
  • VRCA United States
  • OTLK United States
  • Employees
  • VRCA N/A
  • OTLK N/A
  • Industry
  • VRCA Biotechnology: Pharmaceutical Preparations
  • OTLK Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • VRCA Health Care
  • OTLK Health Care
  • Exchange
  • VRCA Nasdaq
  • OTLK Nasdaq
  • Market Cap
  • VRCA 43.0M
  • OTLK N/A
  • IPO Year
  • VRCA 2018
  • OTLK 2016
  • Fundamental
  • Price
  • VRCA $0.49
  • OTLK $1.53
  • Analyst Decision
  • VRCA Hold
  • OTLK Strong Buy
  • Analyst Count
  • VRCA 5
  • OTLK 5
  • Target Price
  • VRCA $6.00
  • OTLK $10.20
  • AVG Volume (30 Days)
  • VRCA 431.6K
  • OTLK 360.4K
  • Earning Date
  • VRCA 05-12-2025
  • OTLK 05-14-2025
  • Dividend Yield
  • VRCA N/A
  • OTLK N/A
  • EPS Growth
  • VRCA N/A
  • OTLK N/A
  • EPS
  • VRCA N/A
  • OTLK N/A
  • Revenue
  • VRCA $7,566,000.00
  • OTLK N/A
  • Revenue This Year
  • VRCA $127.58
  • OTLK N/A
  • Revenue Next Year
  • VRCA $88.06
  • OTLK $288.46
  • P/E Ratio
  • VRCA N/A
  • OTLK N/A
  • Revenue Growth
  • VRCA 47.66
  • OTLK N/A
  • 52 Week Low
  • VRCA $0.38
  • OTLK $0.87
  • 52 Week High
  • VRCA $11.41
  • OTLK $9.29
  • Technical
  • Relative Strength Index (RSI)
  • VRCA 47.66
  • OTLK 60.12
  • Support Level
  • VRCA $0.45
  • OTLK $1.30
  • Resistance Level
  • VRCA $0.59
  • OTLK $1.68
  • Average True Range (ATR)
  • VRCA 0.08
  • OTLK 0.13
  • MACD
  • VRCA 0.00
  • OTLK 0.04
  • Stochastic Oscillator
  • VRCA 26.74
  • OTLK 75.81

About VRCA Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.

Share on Social Networks: